Stockscreener 앱 받기
4.54
0.44%
-0.02
시간 외 거래:
4.54
전일 마감가:
$4.56
열려 있는:
$4.55
하루 거래량:
190.52K
Relative Volume:
0.41
시가총액:
$278.83M
수익:
$45.15M
순이익/손실:
$-39.23M
주가수익비율:
-2.4822
EPS:
-1.829
순현금흐름:
$-18.93M
1주 성능:
+7.58%
1개월 성능:
-0.22%
6개월 성능:
-8.65%
1년 성능:
+7.33%
1일 변동 폭
$4.38
$4.59
1주일 범위
$4.12
$4.59
52주 변동 폭
$2.20
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
명칭
Trisalus Life Sciences Inc
전화
415 336 8917
주소
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.54 | 265.32M | 45.15M | -39.23M | -18.93M | -1.829 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 개시 | Lake Street | Buy |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-11 | 개시 | ROTH MKM | Buy |
| 2024-10-25 | 개시 | Northland Capital | Outperform |
| 2024-09-16 | 개시 | Oppenheimer | Outperform |
| 2024-05-30 | 개시 | Canaccord Genuity | Buy |
모두보기
Trisalus Life Sciences Inc 주식(TLSI)의 최신 뉴스
TriSalus Life Sciences Inc (TLSI) Cash Flow - TradingKey
TriSalus Life Sciences Inc (TLSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
TriSalus Life Sciences Inc (TLSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TriSalus Life Sciences Inc (TLSI) Balance Sheet - TradingKey
TriSalus Life Sciences Inc (TLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TriSalus Life Sciences Inc (TLSI) Income Statement - TradingKey
TLSI|TriSalus Life Sciences Inc|Price:4.360|Chg%:+0.040 - TradingKey
TLSI|TriSalus Life Sciences Inc|Price:4.220|Chg%:-0.050 - TradingKey
TriSalus Life Sciences, Inc. Revenue Breakdown – NASDAQ:TLSI - TradingView
TriSalus Life Sciences Inc (TLSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TriSalus Life Sciences Initiates PREDICTT Clinical Trial - Medical Product Outsourcing
Lobbying Update: $90,000 of TRISALUS LIFE SCIENCES lobbying was just disclosed - Quiver Quantitative
Press Release: TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call - Moomoo
TriSalus Life Sciences to host Q2FY26 financial results call - scanx.trade
TriSalus sets Aug. 6 webcast for second-quarter results - Stock Titan
TriSalus Life Sciences (TLSI) Holds Near Support Amid Modest Uptick – Biotech Sector in FocusAnchored VWAP - dars.gov.et
TriSalus Life Sciences (TLSI) Edges Higher as Stock Tests Key Resistance LevelsLow Risk Entry Stocks - dars.gov.et
Price to sales forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSI - TradingView
TriSalus Life Sciences, Inc. (TLSI) reports Q1 loss, lags revenue estimates - MSN
TLSIW SEC FilingsTriSalus Life Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
First Light Asset Management, Mathew Arens report 10.74% stake in TriSalus (TLSI) - Stock Titan
Form 4 TriSalus Life Sciences Inc For: 6 July By Investing.com - Investing.com Nigeria
TriSalus (TLSI) CFO has shares withheld to cover RSU tax obligations - Stock Titan
TriSalus Life Sciences, Inc. Warrant 2023-04.08.2028 on TriSalus Life Sciences Financial Disclosures & SEC Filings - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages TriSalus Life Scien - The National Law Review
TriSalus Life Sciences (TLSI) Stock Analysis Report | Financials & Insights - Benzinga
TriSalus (TLSI) CEO Mary Szela acquires 3,990 ESPP shares, now holds 1.08M - Stock Titan
TriSalus Life Sciences (TLSI) CCO acquires 561 ESPP shares - Stock Titan
Price to earnings forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSI - TradingView
Form 4 TriSalus Life Sciences Inc For: 29 June By Investing.com - Investing.com Canada
TriSalus Life Sciences (TLSI) CMO awarded RSUs and 120,000-share option grant - Stock Titan
TriSalus (TLSI) CMO discloses common stock and option holdings in Form 3 - Stock Titan
TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
TriSalus Life Sciences, Inc.(NasdaqGM: TLSI) dropped from Russell 3000 Value Benchmark - marketscreener.com
TriSalus Life Sciences, Inc.(NasdaqGM: TLSI) dropped from Russell 2500 Value Benchmark - marketscreener.com
TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
TriSalus Life Sciences, Inc.(NasdaqGM:TLSI) dropped from Russell 3000E Value Benchmark - marketscreener.com
TriSalus Life Sciences, Inc. Actuals & Estimates (NASDAQ:TLSI) - TradingView
TLSI Forecast — Price Target — Prediction for 2027 - TradingView
Canaccord reiterates TriSalus stock Buy rating after KOL event - Investing.com UK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc.TLSI - PR Newswire
Canaccord reiterates TriSalus stock Buy rating after KOL event By Investing.com - Investing.com Australia
CCORF Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
TriSalus Life Sciences Warrants (TLSIW) Dip 3.8% Toward Support as Trading Activity Remains LightDealer Gamma - dars.gov.et
TriSalus Life Sciences (TLSI) Gains 3.23% as Shares Test Resistance at $4.37Ichimoku Kumo Twist - dars.gov.et
Pomerantz investigates TriSalus over revenue dr... - Pluang
TriSalus Life Sciences Inc (TLSIW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TLSI News | TRISALUS LIFE SCIENCES INC (NASDAQ:TLSI) - ChartMill
TriSalus Life Sciences Inc (TLSIW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TriSalus Life Sciences Inc (TLSIW) Institutional Confidence - TradingKey
Trisalus Life Sciences Inc (TLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Trisalus Life Sciences Inc 주식 (TLSI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wahlstrom Mats | Director |
May 15 '26 |
Buy |
2.53 |
60,000 |
151,800 |
147,555 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
410,000 |
1,025,000 |
1,240,722 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
200,000 |
500,000 |
399,698 |
| Szela Mary T | CEO and President |
May 15 '26 |
Buy |
2.59 |
39,682 |
102,776 |
1,065,215 |
| Patience David | Chief Financial Officer |
May 15 '26 |
Buy |
2.43 |
7,100 |
17,253 |
275,757 |
| Gordon Gary B. | Director |
May 15 '26 |
Buy |
2.46 |
10,000 |
24,600 |
72,510 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 12 '26 |
Sale |
4.09 |
1,772 |
7,247 |
97,637 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 11 '26 |
Sale |
4.13 |
1,162 |
4,799 |
99,409 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 16 '26 |
Sale |
4.12 |
273 |
1,125 |
97,364 |
| Cox Bryan F. | Chief of Research |
Mar 12 '26 |
Sale |
4.09 |
1,467 |
6,000 |
163,994 |
1.04%
11.95%
자본화:
|
볼륨(24시간):